Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1691

Novel peptides to promote wound healing and neuroprotection

Inventors: Robert D'Amato, Avner Adini

Invention Types: Therapeutics

Research Areas: Degenerative Disease, Surgery/Wound Healing

Keywords: Composition of Matter, Peptide

For More Information Contact:  Dietz, Ryan

 

Invention Description:

Drs. D'Amato and Adini tested synthetic short peptides from a well-known membrane bound protein. They found that a 12-mer peptide derived from the extracellular domain was able to dramatically stimulate VEGF binding to endothelial cells, to enhance cell proliferation in vitro, and cell migration and angiogenesis in vivo. This peptide promoted wound healing by 50% over control in the diabetic mouse wound healing model. Interestingly, the peptide also increased neurite outgrowth in primary cortical neuronal cells. Drs. D'Amato and Adini are currently exploring various peptide designs to further optimize activity and are expanding testing to other in vivo models of wound healing and neurodegeneration.

Applications:

These peptides could be clinically useful therapeutic agents for wound healing and for neurodegeneration. Chronic wounds, such as diabetic ulcers, affect an estimated 5.7 million patients in the U.S. and cost the healthcare system approximately $20B annually. Neurodegenerative diseases, including Parkinson's, Alzheimer's, Huntington's and ALS, affect millions of patients and although they are the subject of intense research, they remain high unmet medical needs. This market is set to more than double to over $10B by 2013. The pro-angiogenic activity of the peptides further suggests that they could also be used for additional applications such as fertility treatments, hypertrophied hearts, erectile dysfunction and tissue engineered constructs.

Competitive Advantages:

• Answers unmet medical needs: available treatment options for chronic wounds are inconvenient and often ineffective; very few therapies approved for neurodegeneration
• Potent activity: accelerated wound closure in a diabetic ulcer model with increased granulation tissue and collagen deposition; promoted significant neurite outgrowth in human primary neuronal cells
• Amenable to topical formulation: would allow convenient wound care
• Large market potential: wound healing and other angiogenic-dependent diseases, and neurodegenerative diseases
• Strong IP position: composition of matter and method of use, long patent life
• Peptide design ongoing: creation of additional composition of matter IP

Business Opportunity:

Exclusive license and/or sponsored research available

Key Publications: Adini A, et al. A novel strategy to enhance angiogenesis in vivo using small VEGF-binding peptide PR1P. Angiogenesis. 2017 Aug;20(3
Adini A, et al. The stem cell marker prominin-1/CD133 interacts with vascular endothelial growth factor and protentiates its action. Angiogenesis. 2013 Apr:16(2)

Related Publications: Pat. US9090797B2

IPStatus: Patented